On Friday, Avidity Biosciences Inc (NASDAQ: RNA) opened higher 9.21% from the last session, before settling in for the closing price of $33.21. Price fluctuations for RNA have ranged from $21.51 to $56.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -34.37% over the last five years. Company’s average yearly earnings per share was noted -36.62% at the time writing. With a float of $109.72 million, this company’s outstanding shares have now reached $120.51 million.
The firm has a total of 391 workers. Let’s measure their productivity. In terms of profitability, gross margin is 92.3%, operating margin of -4853.44%, and the pretax margin is -4136.0%.
Avidity Biosciences Inc (RNA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Avidity Biosciences Inc is 8.98%, while institutional ownership is 107.56%. The most recent insider transaction that took place on Jun 17 ’25, was worth 27,549. In this transaction Chief Program Officer of this company sold 911 shares at a rate of $30.24, taking the stock ownership to the 50,392 shares. Before that another transaction happened on Jun 17 ’25, when Company’s Officer proposed sale 911 for $29.80, making the entire transaction worth $27,148.
Avidity Biosciences Inc (RNA) Earnings and Forecasts
This company achieved a net margin of -2957.71 while generating a return on equity of -33.47. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -36.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.18% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Check out the current performance indicators for Avidity Biosciences Inc (RNA). In the past quarter, the stock posted a quick ratio of 16.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 489.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -4.40 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Analysing the last 5-days average volume posted by the [Avidity Biosciences Inc, RNA], we can find that recorded value of 2.62 million was better than the volume posted last year of 1.58 million. As of the previous 9 days, the stock’s Stochastic %D was 63.84%.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 89.51%, which indicates a significant increase from 84.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.00 in the past 14 days, which was higher than the 1.98 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.43, while its 200-day Moving Average is $33.89. Now, the first resistance to watch is $38.33. This is followed by the second major resistance level at $40.40. The third major resistance level sits at $43.20. If the price goes on to break the first support level at $33.46, it is likely to go to the next support level at $30.66. Should the price break the second support level, the third support level stands at $28.59.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
There are currently 120,520K shares outstanding in the company with a market cap of 4.37 billion. Presently, the company’s annual sales total 10,900 K according to its annual income of -322,300 K. Last quarter, the company’s sales amounted to 1,570 K and its income totaled -115,770 K.
